Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 13;3(4):418–435. doi: 10.1038/s43587-023-00379-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 4 — (a) Flow cytometry gating strategy for SARS-CoV-2 epitope specific CD8 T cells. (b) Flow cytometry gating strategy for SARS-CoV-2 epitope specific and GZMB+ CD8 T cells. (c) Representative data for detection of epitope specific CD8 T cells in the HLA-A2⁺ healthy donors before and after second doses (Day 7 and Day 50) of inactivated SARS-CoV-2 vaccine with tetramers prepared using SARS-CoV-2 epitopes. Variant strain IDs are listed in Fig. 2a. A: ancestral; M: mutated. The flow cytometry gating strategy is shown in (a). (d) Trends in tetramer+GZMB+ T cells production with age in young and old groups after the second dose vaccination. n = 6 individuals for each group, and each individual with 7 experiments corresponding to 7 distinct epitopes as listed in Fig. 5c.